Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,563,664
  • Shares Outstanding, K 39,387
  • Annual Sales, $ 53,020 K
  • Annual Income, $ -36,560 K
  • 60-Month Beta 1.54
  • Price/Sales 24.63
  • Price/Cash Flow N/A
  • Price/Book 5.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.84
  • Number of Estimates 5
  • High Estimate -0.30
  • Low Estimate -1.14
  • Prior Year 0.29
  • Growth Rate Est. (year over year) -389.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.80 +5.03%
on 02/27/20
49.58 -19.93%
on 02/10/20
-3.84 (-8.82%)
since 01/28/20
3-Month
35.81 +10.86%
on 01/13/20
52.75 -24.74%
on 01/22/20
-3.25 (-7.57%)
since 11/27/19
52-Week
14.05 +182.56%
on 03/06/19
52.75 -24.74%
on 01/22/20
+24.58 (+162.57%)
since 02/28/19

Most Recent Stories

More News
Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ZYME : 39.70 (unch)
Zymeworks to Present at Raymond James 41st Annual Institutional Investors Conference

Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Raymond James Institutional...

ZYME : 39.70 (unch)
Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters' Over-Allotment Option to Purchase Additional Shares

Zymeworks Inc. (NYSE: ZYME), a clinical stage biopharmaceutical company developing multifunctional biotherapeutics ("Zymeworks" or the "Company"), announced today the closing of its previously announced...

ZYME : 39.70 (unch)
Zymeworks Announces Pricing of $279.0 Million Public Offering

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics ("Zymeworks" or the "Company"), announced today the pricing of its previously-announced...

ZYME : 39.70 (unch)
Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants

Zymeworks Inc. (NYSE: ZYME) ("Zymeworks" or the "Company"), a clinical'stage biopharmaceutical company developing multifunctional biotherapeutics, has today filed a preliminary prospectus supplement (the...

ZYME : 39.70 (unch)
Zymeworks Highlights 2019 Achievements and Announces Corporate Priorities

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2019 and updated its corporate priorities....

ZYME : 39.70 (unch)
Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance(R) (palbociclib)

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the initiation of a Phase 2 trial evaluating ZW25 combination therapy and...

ZYME : 39.70 (unch)
Zymeworks to Present at the J.P. Morgan Healthcare Conference 2020

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will present a corporate overview and updated...

JPM : 119.40 (-1.62%)
ZYME : 39.70 (unch)
Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single agent ZW25 in heavily pretreated patients...

BGNE : 154.99 (-1.93%)
ZYME : 39.70 (unch)
Zymeworks Announces Selection of ZW25 Abstract for Mini Oral Presentation at the European Society for Medical Oncology Asia (ESMO Asia) Congress

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the selection of an abstract highlighting updated single agent data from...

ZYME : 39.70 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ZYME with:

Business Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 42.70
1st Resistance Point 41.20
Last Price 39.70
1st Support Level 38.00
2nd Support Level 36.30

See More

52-Week High 52.75
Last Price 39.70
Fibonacci 61.8% 37.97
Fibonacci 50% 33.40
Fibonacci 38.2% 28.83
52-Week Low 14.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar